Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Research & Development
Adaptimmune Therapeutics PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Research & Development
-$125.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Research & Development
-$150.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-104%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Research & Development
-$238.3m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Research & Development
-$119m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Research & Development
-£15.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
6%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Research & Development
£9.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Adaptimmune Therapeutics PLC
Glance View
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.
See Also
What is Adaptimmune Therapeutics PLC's Research & Development?
Research & Development
-125.2m
USD
Based on the financial report for Jun 30, 2025, Adaptimmune Therapeutics PLC's Research & Development amounts to -125.2m USD.
What is Adaptimmune Therapeutics PLC's Research & Development growth rate?
Research & Development CAGR 5Y
-6%
Over the last year, the Research & Development growth was 15%. The average annual Research & Development growth rates for Adaptimmune Therapeutics PLC have been 1% over the past three years , -6% over the past five years .
